The National Comprehensive Cancer Network released updated guidelines for a variety of B-cell lymphomas, including follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma. READ MORE

Author Insights

While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.

READ MORE

CAR-T

The ICER has released a scoping document that will compare the clinical effectiveness and value of multiple CAR-T cell treatments under review by the FDA.

READ MORE

A recent study reported an ORR of 71% in patients with CLL treated with anti-CD19 CAR-T cell therapy after prior treatment failure.

READ MORE

Standardized CD19-specific CAR-modified T cells along with chemotherapy can more effectively guide treatment and improve response in patients with relapsed and refractory B cell non-Hodgkin's lymphoma.

READ MORE

News

A recent study found that a biosimilar provides improved outcomes without increased risk of toxicity for patients with DLBCL and treatment-induced neutropenia.

READ MORE

The US Food and Drug Administration has approved the second CAR T-cell therapy, indicated for certain types of non-Hodgkin lymphoma.

READ MORE

The US Food and Drug Administration (FDA) has made the first gene therapy available, marking their approval of a new approach to the treatment of cancer.

READ MORE

Resources

The National Comprehensive Cancer Network released updated guidelines for a variety of B-cell lymphomas, including follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma.

READ MORE